Novel Nystatin A1 derivatives exhibiting low host cell toxicity and antifungal activity in an in vitro model of oral candidosis
- 547 Downloads
Opportunistic oral infections caused by Candida albicans are frequent problems in immunocompromised patients. Management of such infections is limited due to the low number of antifungal drugs available, their relatively high toxicity and the emergence of antifungal resistance. Given these issues, our investigations have focused on novel derivatives of the antifungal antibiotic Nystatin A1, generated by modifications at the amino group of this molecule. The aims of this study were to evaluate the antifungal effectiveness and host cell toxicity of these new compounds using an in vitro model of oral candidosis based on a reconstituted human oral epithelium (RHOE). Initial studies employing broth microdilution, revealed that against planktonic C. albicans, Nystatin A1 had lower minimal inhibitory concentration than novel derivatives. However, Nystatin A1 was also markedly more toxic against human keratinocyte cells. Interestingly, using live/dead staining to assess C. albicans and tissue cell viability after RHOE infection, Nystatin A1 derivatives were more active against Candida with lower toxicity to epithelial cells than the parent drug. Lactate dehydrogenase activity released by the RHOE indicated a fourfold reduction in tissue damage when certain Nystatin derivatives were used compared with Nystatin A1. Furthermore, compared with Nystatin A1, colonisation of the oral epithelium by C. albicans was notably reduced by the new polyenes. In the absence of antifungal agents, confocal laser scanning microscopy showed that C. albicans extensively invaded the RHOE. However, the presence of the novel derivatives greatly reduced or totally prevented this fungal invasion.
KeywordsCandida albicans Antifungals Nystatin A1 Candidosis Oral infections Cytotoxicity
We would like to thank Mrs Kath Allsopp for processing and sectioning tissue samples. We are also grateful to Mr Marc Isaacs for his assistance with confocal laser scanning microscopy. The project was financed by the National Science Centre (Poland) based on the Grant no. DEC-2011/01/N/NZ1/05269 (PRELUDIUM: pre-doctoral grant).
- 2.Joint United Nations Programme on HIV/AIDS (UNAIDS) and World Health Organization (WHO) (2009) AIDS epidemic update: November 2009, Geneva, SwitzerlandGoogle Scholar
- 4.World Health Organization (2013) Diabetes Programme: fact sheet N°312. http://www.who.int/diabetes/en/. Updated March 2013, Geneva, Switzerland
- 21.Borowski E, Salewska N, Boros-Majewska J, Milewska M, Wysocka M, Milewski S, Składanowski A, Treder A, Sadowska E, Łacka I (2013) Semisynthetic derivatives of Nystatin A1. PCT/EP2013/054621; WO 2013/132014 A1 (12 September 2013)Google Scholar
- 24.Falkowski L, Kowszyk-Gindifer Z, Plóciennik Z, Zieliński J, Dahlig H, Golik J, Jakobs E, Kołodziejczyk P, Bylec E, Roślik-Kamińska D, Wagner W, Pawlak J, Borowski E (1980) Salts of N-glycosyl derivatives of polyene macrolides, especially N-methylglucamine salts as well as the method of their preparation. Patent USA 4195172 AGoogle Scholar
- 25.The National Committee for Clinical and Laboratory Standards (2002) Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts; Approved Standard-Second Edition M27-A2. NCCLS, 2002, Wayne, PA, USAGoogle Scholar
- 28.Ōmura S (1984) Macrolide Antibiotics: Chemistry, Biology, and Practice. Academic Press, OrlandoGoogle Scholar
- 32.Barrat G, Bretagne S (2007) Optimizing efficacy of Amphotericin B through nanomodification. Int J Nanomedicine 2:301–313Google Scholar
- 36.Bruheim P, Borgos SE, Tsan P, Stella H, Ellingsen TE, Lancelin JM, Zotchev SB (2004) Chemical diversity of polyene macrolides produced by Streptomyces noursei ATCC 11455 and recombinant strain ERD44 with genetically altered polyketide synthase NysC. Antimicrob Agents Chemother 48:4120–4129PubMedCrossRefPubMedCentralGoogle Scholar
- 39.Szlinder-Richert J, Mazerski J, Cybulska B, Grzybowska J, Borowski E (2001) MFAME, N-methyl-N-D-fructosyl amphotericin B methyl ester, a new amphotericin B derivative of low toxicity: relationship between self-association and effects on red blood cells. Biochim Biophys Acta 1528:15–24PubMedCrossRefGoogle Scholar